Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high‐risk relapsed/refractory Hodgkin lymphoma
Authors:
Open Access
- 30 April 2025
- journal article
- Published by Wiley in HemaSphere
- Vol. 9 (5) , e70126
Abstract
Nivolumab is an anti‐PD‐1 antibody that is effective in patients with relapsed/refractory (RR) classic Hodgkin lymphoma (cHL). We previously showed PET‐adapted sequential nivolumab ± ifosfamide, carboplatin, and etoposide (ICE) chemotherapy as the first salvage in RR cHL was a safe and effective bridge to autologous stem cell transplant (ASCT) (cohort A). We then tested a non‐PET‐adapted schema where all patients received nivolumab + ICE (cohort B). In this study, we present results from cohort B. Patients with high‐risk RR cHL after frontline treatment received 240 mg nivolumab followed by 2–3 cycles of NICE (240 mg nivolumab day 1, standard doses of ICE). High‐risk disease was defined as having one of the following: primary refractory cHL, relapse within 1 year of completing frontline therapy, B symptoms at relapse, extranodal disease at relapse, or frontline brentuximab vedotin use. PET/CT was performed after nivolumab × 1 and NICE × 2. Responding patients (complete response [CR] or partial response) were intended to proceed to ASCT. The primary endpoint was CR rate per 2014 Lugano classification. A total of 35 patients were enrolled, all of whom were evaluable for safety and efficacy. Overall response rate and CR were 100% and 86%, respectively; 2‐year progression‐free survival (PFS) and overall survival (OS) were 88% and 100%, respectively. Thirty‐two patients proceeded to ASCT directly after NICE; 2‐year post‐ASCT PFS and OS were 94% and 100%, respectively. Immune‐related toxicities were all grades 1–2, and no patient discontinued treatment for toxicity. Nivolumab/NICE is a highly effective salvage regimen and bridges patients effectively to ASCT.Keywords
Funding Information
- National Institutes of Health (P50 CA107399‐11A1)
- Bristol-Myers Squibb
This publication has 16 references indexed in Scilit:
- Response-adapted anti-PD-1–based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICEBlood, 2022
- Chemotherapy after PD‐1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamicsBritish Journal of Haematology, 2022
- Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin LymphomaJournal of Clinical Oncology, 2021
- Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study resultsBlood, 2021
- Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphomaBlood Advances, 2021
- Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapseBlood, 2018
- Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphomaAnnals of Oncology, 2017
- PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 studyThe Lancet Oncology, 2015
- Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trialThe Lancet, 2002
- Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trialThe Lancet, 1993